Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for REGN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for REGN and 80,000+ other tickers.
See exactly how REGN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for REGN and 80,000+ other tickers.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic…
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.
Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) insider Andrew Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at